Trial reportFrontiers in medicine2026
The effect of esketamine on sleep disorders in parturients undergoing cesarean section under general anesthesia: a single-center, randomized, double-blind, placebo-controlled prospective study.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the primary effect of esketamine on postoperative sleep disorder (PSD) at 3 days after surgery, as well as its secondary effects on pain and depressive symptoms. Methods: A total of 140 parturients who underwent elective cesarean delivery under general anesthesia were enrolled and randomized 1:1 to the esketamine or placebo group. After delivery, blinded anaesthesiologists administered a continuous infusion of esketamine (0.3 mg/kg/h) or an equal volume of normal saline. We compared baseline data, anesthesia/surgery indicators, postoperative PSQI scores, sleep NRS scores, incidences of PSD, pain NRS scores and postpartum depression (EPDS) between the groups. We also evaluated adverse reactions and maternal-neonatal complications and performed multivariate logistic regression for PSD risk factors. Results: At 3 and 7 days after surgery, the PSQI scores, NRS scores, incidence of PSD, and incidence of postpartum depression in the esketamine group were significantly lower than those in the control group ( Conclusion: Continuous intraoperative esketamine infusion reduced the incidence of 3-day postoperative sleep disorders and improves sleep quality, while concurrently enhancing analgesic efficacy and ameliorating postpartum depression outcomes in parturients undergoing cesarean section under general anesthesia. Clinicians should prioritize screening for prenatal sleep disturbances and implement early preventive interventions. Clinical Trial Registration: https://clinicaltrials.gov/, Identifier [ChiCTR23000 78490].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.